Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

U.S. Urges Doctors to Write More Rx for Overdose Antidote

By Carla K Johnson, AP Medical Writer | December 20, 2018

A Narcan nasal device that delivers naloxone. (AP Photo/Mary Altaffer)

The U.S. government told doctors Wednesday to consider prescribing medications that reverse overdoses to many more patients who take opioid painkillers in a move that could add more than $1 billion in health care costs.

Assistant Secretary for Health Brett Giroir, a doctor appointed by President Donald Trump, announced the guidance, saying it’s important for doctors to discuss overdose dangers with patients.

Prescribing naloxone such as Narcan along with opioids forces a conversation that will lead to “a more informed decision by the patient,” he said.

The action comes a day after a close vote from a Food and Drug Administration expert panel endorsing the idea of rewriting opioid drug labels to include a naloxone recommendation for many or all patients. An FDA document said such a move could add more than $1 billion in health care costs.

“Even at a billion, it would be an investment that is well worth it,” Giroir said.

More than 47,600 Americans died of opioid overdoses last year, a toll that has been rising for two decades. The street drug fentanyl is the top killer today, but prescription painkillers are still a problem, contributing to nearly 15,000 overdose deaths last year.

Naloxone comes in a nasal spray, an injection and an automatic injector. The Narcan nasal spray costs about $125 for a two-dose kit, although government programs can get it for less. The automatic injector can cost as much as $4,000 per kit, although its maker recently authorized a cheaper generic version.

Critics said prescribing the antidote to pain patients does not address the growing share of fatal overdoses caused by illicit opioids, and could cause shortages for programs that hand out the kits to street drug users.

It “will have the unintended consequence of derailing efforts to provide naloxone to the very effective community programs we know are successful in saving lives,” said Dr. Raeford E. Brown Jr., who heads an expert panel advising the FDA.

The new guidance tells doctors to consider prescribing the antidote to patients on high doses of opioids, heavy drinkers, people with sleep apnea and other breathing problems, people taking benzodiazepines such as Xanax and people with addiction or mental health problems.

It expands upon a similar recommendation from the Centers for Disease Control and Prevention.

In April, U.S. Surgeon General Jerome Adams issued the office’s first national public health advisory in 13 years, calling on more Americans to start carrying naloxone and urging more federal money to be dedicated to broadening access.

Most states allow people to get naloxone from a pharmacy or community program under a statewide prescription and some states require doctors to also prescribe naloxone to patients on high doses of opioids.

The FDA is working toward an over-the-counter version of naloxone.

Brown said the government should use its emergency authority to buy and distribute large quantities of naloxone and immediately make it available over the counter. Trump directed the health agency to declare the opioid crisis a public health emergency last year.

“That’s the difference between declaring a public health emergency and actually acting as if there’s a public health emergency,” Brown said.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE